Molecular mechanisms underlying the antiatherosclerotic and antidiabetic effects of probucol, succinobucol, and other probucol analogues

Current Opinion in Lipidology

Volumn 20, Issue 3, 2009, Pages 227-235

  Stacker, Roland ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Cardiovascular disease; Heme oxygenase 1; High density lipoprotein cholesterol; Succinobucol

Indexed keywords

4,4' (METHYLENEDITHIO)BIS(2,6 DI TERT BUTYLPHENOL); ANTILIPEMIC AGENT; BM 150639; CHOLESTEROL ESTER TRANSFER PROTEIN; HEME OXYGENASE 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MDL 27272; METFORMIN; PACLITAXEL; PLACEBO; PROBUCOL; PROBUCOL BISPHENOL; PROBUCOL DITHIOBISPHENOL; PROBUCOL SELENOTHIOBISPHENOL; PROBUCOL SUCCINATE; RAPAMYCIN; SUCCINOBUCOL; UNCLASSIFIED DRUG;

ALLOXAN DIABETES MELLITUS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTERY INTIMA PROLIFERATION; ATHEROMA; ATHEROSCLEROSIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG ELUTING STENT; DRUG MECHANISM; DRUG STRUCTURE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HEART ATRIUM FIBRILLATION; HUMAN; HYPERINSULINEMIA; IN-STENT RESTENOSIS; INSULIN DEPENDENT DIABETES MELLITUS; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; STENT THROMBOSIS; STREPTOZOCIN DIABETES; THROMBOSIS; THROMBOSIS PREVENTION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANIMALS; ATHEROSCLEROSIS; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; PROBUCOL;

EID: 67049172415     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e32832aee68     Document Type: Review

References (74)

1. Stacker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004; 84:1381-1478.
2. Tanous D, Hime N, Stacker R. Antiatherosclerotic and antidiabetic properties of probucol and related compounds. Redox Rep 2008; 13:48-59. A recent review that deals with the same topic as the present review, but in a more extensive manner.
3. Walldius G, Erikson U, Olsson AG, et al. The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol 1994; 74:875-883.
4. Barnhart JW, Wagner ER, Jackson RL. The synthesis, metabolism, and biological activity of probucol and its analogs. In: Witiak DT, Newman HAI, Feller DR, editors. Antilipidemic drugs. Amsterdam: Elsevier; 1991. pp. 277-298.
5. Guo J, Massaeli H, Li W, et al. Identification of IKr and its trafficking disruption induced by probucol in cultured neonatal rat cardiomyocytes. J Pharmacol Exp Ther 2007; 321:911-920. This is a detailed study, describing a novel mechanism by which probucol may prolong the QT interval. The study is based entirely on in-vitro experiments, the in-vivo relevance of which requires confirmation.
6. Meng CQ, Somers PK, Rachita CL, et al. Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis. Bioorg Med Chem Lett 2002; 12:2545-2548.
7. Barnhart JW, Sefranka JA, Mcintosh DD. Hypocholesterolemic effect of 4,4'-(isopropylidenedithio)-bis(2,6-di-t-butylphenol) (Probucol). Am J Clin Nutr 1970; 23:1229-1233.
8. Yamamoto A, Matsuzawa Y, Yokoyama S, et al. Effects of probucol on xanthomata regression in familial hypercholesterolemia. Am J Cardiol 1986;57:29H-35H.
9. Sawayama Y, Shimizu C, Maeda N, et al. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). J Am Coll Cardiol 2002; 39:610-616.
10. Sawayama Y, Maeda S, Ohnishi H, et al. Effect of probucol on elderly hypercholesterolemia patients in the FAST study. Fukuoka Igaku Zasshi 2006;97:15-24.
11. Yamashita S, Hbujo H, Arai H, er al. Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan. J Atheroscler Thromb 2008; 15:292-303. Although small in size, this study is important because it provides strong evidence that long-term treatment with probucol, in conjunction with statins, is without harm and can result in significant benefit in a group of patients with heterozygous familial hypercholesterolemia.
12. Glagov S, Weisenberg E, Zarins CK, et al. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987; 316:1371-1375.
13. Wu BJ, Di Girolamo N, Beck K, et al. Probucol [4,4'-[(1- methylethylidene)- bis(thio)]bis-[2,6-bis(1,1-dimethylethyl)phenol]] inhibits compensatory remodeling and promotes lumen loss associated with atherosclerosis in apolipoprotein E-deficient mice. J Pharmacol Exp Ther 2007; 321:477-484. This study provides novel insight into potential vascular effects of probucol that might help explain the apparent discrepancy between earlier studies addressing the antiatherosclerotic activity of probucol in humans.
14. Kita T, Nagano Y, Yokode M, et al. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci U S A 1987; 84:5928-5931.
15. Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci U S A 1987; 84:7725-7729.
16. Braun A, Zhang S, Miettinen HE, et al. Probucol prevents early coronary heart disease and death in the high-density lipoprotein receptor SR-BI/apolipopro-tein E double knockout mouse. Proc Natl Acad Sci U S A 2003; 100:7283-7288.
17. Zhang SH, Reddick RL, Avdievich E, et al. Paradoxical enhancement of atherosclerosis by probucol treatment in apolipoprotein E-deficient mice. J Clin Invest 1997; 99:2858-2866.
18. Witting PK, Pettersson K, Letters J, et al. Site-specific antiatherogenic effect of probucol in apolipoprotein E deficient mice. Arterioscler Thromb Vase Biol 2000; 20:e26-e33.
19. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350:221-231.
20. Moreno R, Fernandez C, Hernandez R, et al. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 2005; 45:954-959.
21. Tardif J-C, Côté G, Lespérance J, et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med 1997; 337:365-372.
22. Yokoi H, Daida H, Kuwabara Y, et al. Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial. J Am Coll Cardiol 1997; 30:855-862.
23. Daida H, Kuwabara Y, Yokoi H, et al. Effect of probucol on repeat revascularization rate after percutaneous transluminal coronary angioplasty (from the Probucol Angioplasty Restenosis Trial [PART]). Am J Cardiol 2000; 86:550-552.
24. Lau AK, Leiohtweis SB, Hume P, et al. Probucol promotes functional reen-dothelialization in balloon-injured rabbit aortas. Circulation 2003; 107:2031-2036.
25. Schneider JE, Berk BC, Gravanis MB, et al. Probucol decreases neointimal formation in a swine model of coronary artery balloon injury. A possible role for antioxidants in restenosis. Circulation 1993; 88:628-637.
26. Tanous D, Bräsen JH, Choy K, et al. Probucol inhibits in-stent thrombosis and neointimal hyperplasia by promoting re- endothelialization. Atherosclerosis 2006; 189:342-349.
27. Sekiya M, Funada J, Watanabe K, et al. Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis. Am J Cardiol 1998;82:144-147.
28. Kim MH, Cha KS, Han JY, et al. Effect of antioxidant probucol for preventing stent restenosis. Catheter Cardiovasc Interv 2002; 57:424-428.
29. Tardif JC, Grégoire J, Schwartz L, et al. Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation 2003; 107:552-558.
30. Nunes GL, Abizaid AC, Theodora MP, et al. Role of probucol in inhibiting intimal hyperplasia after coronary stent implantation: a randomized study. Am Heart J 2006; 152:914 e1-914 e7.
31. Côté G, Tardif JC, Lesperance J, et al. Effects of probucol on vascular remodeling after coronary angioplasty. Multivitamins and Protocol Study Group. Circulation 1999; 99:30-35.
32. Thybo P, Pedersen BL, Hovgaard L, et al. Characterization and physical stability of spray dried solid dispersions of probucol and PVP-K30. Pharm Dev Technol 2008; 13:375-386.
33. Steigerwald K, Merl S, Kastrati A, et al. The preclinical assessment of rapamycin-eluting, durable polymer-free stent coating concepts. Biomaterials 2009; 30:632-637. The study describes, for the first time, the development of a stent dually coated with rapamycin and probucol.
34. Ablamunits V, Sherry NA, Kushner JA, et al. Autoimmunity and beta cell regeneration in mouse and human type 1 diabetes: the peace is not enough. Ann N Y Acad Sci 2007; 1103:19-32.
35. Delaigle AM, Senou M, Guiot Y, et al. Induction of adiponectin in skeletal muscle of type 2 diabetic mice: in vivo and in vitro studies. Diabetologia 2006; 49:1311-1323.
36. Zhang X, Li Z, Liu D, et al. Effects of probucol on hepatic tumor necrosis factor-α, interleukin-6 and adiponectin receptor-2 expression in diabetic rats. J Gastroenterol Hepatol 2009 (in press).
37. Endo K, Miyashita Y, Sasaki H, et al. Probucol delays progression of diabetic nephropathy. Diabetes Res Clin Pract 2006; 71:156-163.
38. Yoshida M, Kimura H, Kyuki K, et al. Combined effect of probucol and insulin on renal damage in diabetic rats fed a high cholesterol diet. Eur J Pharmacol 2006;548:174-180.
39. Soulis-Liparota T, Cooper ME, Dunlop M, et al. The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat. Diabetologia 1995;38:387-394.
40. Noto H, Kawamura M, Hashimoto Y, et al. Modulation of HDL metabolism by probucol in complete cholesteryl ester transfer protein deficiency. Atherosclerosis 2003; 171:131-136.
41. Miettinen HE, Rayburn H, Krieger M. Abnormal lipoprotein metabolism and reversible female infertility in HDL receptor (SR-BI)-deficient mice. J Clin Invest 2001; 108:1717-1722.
42. Gunter C, Frank M, Tian Y, et al. Probucol therapy overcomes the reproductive defect in CTP: phosphocholine cytidylyltransferase beta2 knockout mice. Biochim Biophys Acta 2007; 1771:845-852. An intriguing study, documenting a second example of how probucol can overcome the fertility defect in a mouse deficient in a gene involved in lipid metabolism.
43. Miida T, Seino U, Miyazaki O, et al. Probucol markedly reduces HDL phos-pholipids and elevated preβ1 -HDL without delayed conversion into α-migrat- ing HDL: putative role of angiopoietin-like protein 3 in probucol-induced HDL remodeling. Atherosclerosis 2008; 200:329-335. This study sheds new light on the way probucol affects HDL metabolism in humans.
44. Rinninger F, Wang N, Ramakrishnan R, et al. Probucol enhances selective uptake of HDL-associated cholesteryl esters in vitro by a scavenger receptor B-l-dependent mechanism. Arterioscler Thromb Vase Biol 1999; 19:1325-1332.
45. Ferns GA, Forster L, Stewart-Lee A, et al. Probucol inhibits mononuclear cell adhesion to vascular endothelium in the cholesterol-fed rabbit. Atherosclerosis 1993; 100:171-181.
46. Choy K, Beck K, Png FY, et al. Processes involved in the site-specific effect of probucol on atherosclerosis in apolipoprotein E gene knockout mice. Arterioscler Thromb Vase Biol 2005; 25:1684-1690.
47. Wu T-C, Chen Y-H, Leu H-B, et al. Carvedilol, a pharmacological antioxidant, inhibits neointimal matrix metalloproteinase-2 and -9 in experimental atherosclerosis. Free Radic Biol Med 2007; 43:1508-1522.
48. Brasen JH, Koenig K, Bach H, et al. Comparison of the effects of alpha-tocopherol, ubiquinone-"] 0 and probucol at therapeutic doses on atherosclerosis in WHHL rabbits. Atherosclerosis 2002; 163:249-259.
49. Pryor WA, Cornicelli JA, Devall U, et al. A rapid screening test to determine the antioxidant potencies of natural and synthetic antioxidants. J Org Chem 1993;58:3521-3532.
50. Witting PK, Wu BJ, Raftery M, et al. Probucol protects against hypochlorite-induced endothelial dysfunction. Identification of a novel pathway of probucol oxidation to a biologically active intermediate. J Biol Chem 2005; 280: 15612-15618.
51. Van Antwerpen P, Neve J, Moreau P, et al. Probucol does not inhibit myeloperoxidase-dependent low-density lipoprotein oxidation as a potent protective effect in atherosclerosis. J Cardiovasc Pharmacol 2007; 50: 350-351.
52. Bjelakovic G, Nikolova D, Gluud LL, et al. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 2007; 297:842-857.
53. Fruebis J, Steinberg D, Dresel HA, et al. A comparison of the antiatherogenic effects of probucol and a structural analogue of probucol in low density lipoprotein receptor-deficient rabbits. J Clin Invest 1994; 94:392-398.
54. Witting PK, Pettersson K, Östlund-Lindqvist A-M, et al. Dissociation of atherogenesis from aortic accumulation of lipid hydro(pero)xides in Watanabe heritable hyperlipidemic rabbits. J Clin Invest 1999; 104:213-220.
55. Wu BJ, Kathir K, Witting PK, et al. Antioxidants protect from atherosclerosis by a heme oxygenase-1 pathway that is independent of free radical scavenging. J Exp Med 2006; 203:1117-1127.
56. Stocker R. Compositions and methods for treating cardiovascular disorders. WO 2006/063408. 2005.
57. Keaney JF Jr, Xu A, Cunningham D, et al. Dietary probucol preserves endothelial function in cholesterol-fed rabbits by limiting vascular oxidative stress and superoxide generation. J Clin Invest 1995; 95:2520-2529.
58. Tagawa T, Urabe Y, Kimura Y, et al. Long-term treatment with probucol improves endothelial function in patients with coronary artery disease. Hypertens Res 2004; 27:311-318.
59. Aubin MC, Carrier M, Shi YF, et al. Role of probucol on endothelial dysfunction of epicardial coronary arteries associated with left ventricular hypertrophy. J Cardiovasc Pharmacol 2006; 47:702-710.
60. Jiang F, Roberts SJ, Datla S, et al. NO modulates NADPH oxidase function via heme oxygenase-1 in human endothelial cells. Hypertension 2006; 48:950-957.
61. Kawamura K, Ishikawa K, Wada Y, et al. Bilirubin from heme oxygenase-1 attenuates vascular endothelial activation and dysfunction. Arterioscler Thromb Vase Biol 2005; 25:155-160.
62. Vita JA, Brennan ML, Gokce N, et al. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation 2004; 110:1134-1139.
63. Stocker R, Huang A, Jeranian E, et al. Hypochlorous acid impairs EDNO bioactivity through a superoxide-dependent mechanism. Arterioscler Thromb Vase Biol 2004; 24:2028-2033.
64. Stocker R, Perrella MA. Heme oxygenase-1. A novel drug target for atherosclerotic diseases? Circulation 2006; 114:2178-2189.
65. Deng YM, Wu BJ, Witting PK, et al. Probucol protects against smooth muscle cell proliferation by upregulating heme oxygenase-1. Circulation 2004; 110:1855-1860.
66. Chen Y-H, Chau L-Y, Chen J-W, et al. Serum bilirubin and ferritin levels link heme oxygenase-1 gene promoter polymorphism and susceptibility to coronary artery disease in diabetic patients. Diabetes Care 2008; 31:1615-1620. One of the studies providing evidence for a potential beneficial effect of elevated HO-1 activity in relation to cardiovascular outcome in patients with type 2 diabetes.
67. Fukui M, Tanaka M, Shiraishi E, et al. Relationship between serum bilirubin and albuminuria in patients with type 2 diabetes. Kidney Int 2008; 74:1197-1201.
68. Sundell CL, Somers PK, Meng CQ, et al. AGI-1067: a multifunctional phenolic antioxidant, lipid modulator, anti-inflammatory and antiatherosclero-tic agent. J Pharmacol Exp Ther 2003; 305:1116-1123.
69. Tardif JC, Gregoire J, L'Allier PL, et al. Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial. Atherosclerosis 2008; 197:480-486. The first study describing the potential antiatherosclerotic activity of a novel probucol analogue in humans.
70. Tardif JC, McMurray JJ, Klug E, et al. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 371:1761-1768. The study describes the outcome of a large phase III study examining the effect of 2 years of administration of the novel probucol analogue, succinobucol, on cardiovascular outcomes. The results presented raise the possibility that succinobucol inhibits diabetes.
71. Kunsch C, Luchoomun J, Grey J Y, et al. Selective inhibition of endothelial and monocyte redox-sensitive genes by AGI-1067: a novel antioxidant and antiinflammatory agent. J Pharmacol Exp Ther 2004; 308:820-829.
72. Luyendyk JP, Piper JD, Tencati M, et al. A novel class of antioxidants inhibit LPS induction of tissue factor by selective inhibition of the activation of ASK1 and MAP kinases. Arterioscler Thromb Vase Biol 2007; 27:1857-1863.
73. Johnson MB, Heineke EW, Rhinehart BL, et al. MDL 29311. Antioxidant with marked lipid- and glucose-lowering activity in diabetic rats and mice. Diabetes 1993;42:1179-1186.
74. Sheetz MJ, Barnhart RL, Jackson RL, et al. MDL 29311, an analog of probucol, decreases triglycerides in rats by increasing hepatic clearance of very-low-density lipoprotein. Metabolism 1994; 43:233-240.